XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), Cetrelimab (JNJ-63723283), Ersodetug (RZ358), MIPLYFFATM (arimoclomol), Acimtamig (AFM13), Ficlatuzumab (AV-299), COM902, Vosaroxin, Aldoxorubicin, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, DSUVIA (sufentanil sublingual tablet), IXINITY, Vidutolimod (CMP-001), MT-0169, RZ-402, G03-52-0, AFM24, Mezagitamab (TAK-079), among others. The Company also acquires milestone and royalty revenue streams on late-stage or commercial assets.
종목 코드 XOMA
회사 이름XOMA Royalty Corp
상장일Jun 06, 1986
설립일2011
CEOMr. Owen P. Hughes, Jr.
직원 수13
유형Ordinary Share
회계 연도 종료Jun 06
주소2200 Powell Street
도시EMERYVILLE
증권 거래소NASDAQ Global Market Consolidated
국가United States of America
우편 번호94608
전화15102047239
웹사이트https://www.xoma.com/
종목 코드 XOMA
상장일Jun 06, 1986
설립일2011
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음